Catalyst Wire Dossier Catalyst Wire Dossier

Telisotuzumab Vedotin

Telisotuzumab Vedotin · AbbVie
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for Telisotuzumab Vedotin, covering 2024-06-26 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer [Phase 2]

See pricing